Cancer News and Research

Latest Cancer News and Research

Neoprobe gamma radiation detection systems featured in RSL peer review in American Journal of Surgery

Neoprobe Corporation, a diversified developer of innovative biomedical surgical oncology products, today announced that its gamma radiation detection system product line, which includes the neo2000® and neoprobe® GDS systems, was featured in a peer reviewed publication characterizing the emergence of the use of radioactive "seeds" to assist in the surgical excision of non-palpable breast lesions.

18 May 2010

Study confirms genetic overlap for susceptibility to COPD and lung cancer

New research shows genes that make smokers more likely to develop chronic obstructive pulmonary disease (COPD), or emphysema, are also closely linked to an increased likelihood of developing lung cancer, according to studies presented today at the American Thoracic Society's annual meeting.

18 May 2010

New DVS radiation measurement device for prostate cancer treatment

John Theurer Cancer Center at Hackensack University Medical Center announced today that it is one of two cancer centers in the tri-state area currently implanting a wireless radiation sensor, known as DVS. John Theurer Cancer Center radiation oncologists can now receive data immediately post- treatment on the precise amount of radiation being delivered to tumors and surrounding tissue for prostate cancer treatments.

18 May 2010

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the new therapeutic strategy effectively targets notoriously intractable leukemia stem cells that often escape standard treatment and are a main factor in disease relapse.

18 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

Cancer Research UK launches new cancer centre in Leeds

LEEDS today joins a unique chain of Cancer Research UK Centres that are being launched across the UK.

18 May 2010

Abviva receives Japanese patent for Mammastatin Serum Assay

Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA).

18 May 2010

Study of link between cell phone use and brain tumours inconclusive

The world's biggest investigation on possible links between cell phone use and brain tumours is inconclusive, according to a Canadian scientist who collaborated on the Interphone International Study Group. Jack Siemiatycki, a professor at the University of Montreal and an epidemiologist at the University of Montreal Hospital Research Center, says restricted access to participants compromised the validity of results of the study to be published in the May 18 International Journal of Epidemiology.

18 May 2010

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

BioSante Pharmaceuticals, Inc. today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines.

18 May 2010

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

Keryx Biopharmaceuticals today announced the publication of an article in the May 12th Journal of the National Cancer Institute, entitled "In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by AKT Inhibitor Perifosine," demonstrating the single agent activity of KRX-0401 (perifosine) in neuroblastoma tumor preclinical models.

18 May 2010

GATC Biotech to sequence samples from pediatric brain tumors for world's largest cancer research project

GATC Biotech to sequence samples from brain tumors in children for the world's largest cancer research project. The aim of the German PedBrainTumor Consortium within the ICGC is to develop innovative diagnostic methods and treatments in order to be able to provide children with therapies which have fewer side effects in future.

18 May 2010

Exosure to organophosphate pesticides associated with increased risk of ADHD in children

Following closely on the heels of the President's Cancer Panel Report exhorting consumers to choose food grown without pesticides or chemical fertilizers, antibiotics, and growth hormones to help decrease their exposure to environmental chemicals that can increase their risk of contracting cancer, a study published in today's issue of the journal Pediatrics concludes that exposure to organophosphate pesticides at levels common among U.S. children may contribute to the prevalence of attention deficit hyperactivity disorder in these children.

18 May 2010

New book offers practical knowledge on celiac disease, gluten-related disorders

A new book from the American Gastroenterological Association offers broad and practical knowledge on celiac disease and gluten-related disorders, empowering those who are undiagnosed and those living with the disease to achieve the best possible health and well-being.

18 May 2010

Pfizer, Washington University announce indications discovery collaboration

In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

18 May 2010

AbstralTM continues strong growth of over 40% in first-quarter 2010

Orexo AB today confirms that its partner, ProStrakan Group plc has announced that AbstralTM continues to show strong sales development in 2010.

18 May 2010

University of Leeds researchers identify natural defence mechanism against heart disease

A natural defence mechanism against heart disease could be switched on by steroids sold as health supplements, according to researchers at the University of Leeds.

18 May 2010

Sutter Health Sac-Sierra Region selects MedAssets' CarePricer patient bill estimation solution

The Sacramento Sierra Region of Sutter Health has selected MedAssets' patient bill estimation solution, CarePricer®, to provide its patients with accurate Patient Friendly Estimates™ at the point-of-access. Using the solution, Sutter Health's seven hospitals in the region will better educate its patients on their responsibilities upfront to improve collections.

18 May 2010

Researchers treat undiagnosed FIM with experimental stem cell transplant

Researchers at the Queensland Institute of Medical Research and the Royal Brisbane Women's Hospital have identified a previously undiagnosed condition and successfully treated it by performing an experimental stem cell transplant.

18 May 2010

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

Patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives, according to researchers at Thomas Jefferson University.

18 May 2010

FDA accepts for filing Sigma-Tau Pharmaceuticals' cysteamine hydrochloride ophthalmic solution NDA

Sigma-Tau Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the company's new drug application (NDA) for its cysteamine hydrochloride ophthalmic solution, an investigational therapy for the treatment of corneal cystine crystals in patients with cystinosis. The FDA also granted the NDA Priority Review status, a designation given to drugs that may provide major advances or a treatment where no adequate therapy exists.

18 May 2010

Cancer News and Research

Latest Cancer News and Research

Neoprobe gamma radiation detection systems featured in RSL peer review in American Journal of Surgery

Study confirms genetic overlap for susceptibility to COPD and lung cancer

New DVS radiation measurement device for prostate cancer treatment

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

Cancer Research UK launches new cancer centre in Leeds

Abviva receives Japanese patent for Mammastatin Serum Assay

Study of link between cell phone use and brain tumours inconclusive

BioSante receives two new US patents covering 2A/Furin technology for expressing proteins

Article demonstrates single agent activity of KRX-0401 in neuroblastoma tumor preclinical models

GATC Biotech to sequence samples from pediatric brain tumors for world's largest cancer research project

Exosure to organophosphate pesticides associated with increased risk of ADHD in children

New book offers practical knowledge on celiac disease, gluten-related disorders

Pfizer, Washington University announce indications discovery collaboration

AbstralTM continues strong growth of over 40% in first-quarter 2010

University of Leeds researchers identify natural defence mechanism against heart disease

Sutter Health Sac-Sierra Region selects MedAssets' CarePricer patient bill estimation solution

Researchers treat undiagnosed FIM with experimental stem cell transplant

Patients who receive H-SRT for recurrent brain cancer live longer: Researchers

FDA accepts for filing Sigma-Tau Pharmaceuticals' cysteamine hydrochloride ophthalmic solution NDA

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in